Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EHSG-KF versus split-thickness skin graft for full-thickness skin defects
2024-512190-27-00Phase 2Completed
- Sponsor
- CUTISS
- Start
- Oct 2024
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of denovoSkin (2 arms), sponsored by CUTISS. Primary endpoint: General scar quality by POSAS observer total score. Started Oct 2024; status: completed.
02
Drugs
denovoSkin
Beyond the preview
Go deeper on 2024-512190-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512190-27-00.